Corbus Q2 net loss $8.8M vs $13.2M YoY; cash $36.6M; pipeline on track

Corbus Pharmaceuticals Holdings, Inc.

2023-Q2 EPS reported -$6.27

Net loss of $8.8M ($2.05 diluted EPS) compared to $13.2M ($3.18) in Q2 2022; operating expenses down $4.1M.
Cash, cash equivalents and investments $36.6M as of June 30, 2023; expected to fund operations through Q2 2024.
CRB-701 Phase 1 dose escalation ahead of schedule in China; completion expected Q4 2023; US trial start accelerated to Q1 2024.
Preliminary PK data for CRB-701 shows longer half-life and lower free MMAE vs published PADCEV data.
CRB-601 IND submission on track for Q4 2023; first patient in Phase 1 expected H1 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Corbus Pharmaceuticals Holdings, Inc. reported the three months ended June 30, 2023 results: net income net loss of approximately $8.8 million, or a net loss per diluted share of $2.05, EPS $2.05.

Period: the three months ended June 30, 2023
Net income: net loss of approximately $8.8 million, or a net loss per diluted share of $2.05
EPS: $2.05
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $8.8 million, or a net loss per diluted share of $2.05, for the three months ended June 30, 2023

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039409

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.